Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.01−0.37 (-10.81%)
Close on Nov 17, 2026Market cap $58.22MP/E –Yield –
Corbus Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Corbus Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $90.26M, up 79.0% year over year. For fiscal 2025 it was $70.10M, up 117.5% from the year before. Over ten years it grew 28.1% a year on average. The highest annual figure on record is $98.27M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.10M | +117.5% |
| FY2024 | Dec 31, 2024 | $32.22M | +3.4% |
| FY2023 | Dec 31, 2023 | $31.17M | +93.1% |
| FY2022 | Dec 31, 2022 | $16.14M | -55.7% |
| FY2021 | Dec 31, 2021 | $36.45M | -62.9% |
| FY2020 | Dec 31, 2020 | $98.27M | +9.7% |
| FY2019 | Dec 31, 2019 | $89.60M | +84.3% |
| FY2018 | Dec 31, 2018 | $48.61M | +86.7% |
| FY2017 | Dec 31, 2017 | $26.04M | +68.7% |
| FY2016 | Dec 31, 2016 | $15.44M | +162.1% |
| FY2015 | Dec 31, 2015 | $5.89M | +369.0% |
| FY2014 | Dec 31, 2014 | $1.26M | +496.0% |
| FY2013 | Dec 31, 2013 | $210.67K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.18M | +105.3% |
| Q1 FY2026 | Mar 31, 2026 | $19.82M | +26.7% |
| Q4 FY2025 | Dec 31, 2025 | $18.41M | +109.5% |
| Q3 FY2025 | Sep 30, 2025 | $20.86M | +93.0% |
| Q2 FY2025 | Jun 30, 2025 | $15.19M | +121.2% |
| Q1 FY2025 | Mar 31, 2025 | $15.64M | +171.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.79M | +25.9% |
| Q3 FY2024 | Sep 30, 2024 | $10.81M | +65.0% |
| Q2 FY2024 | Jun 30, 2024 | $6.87M | +61.6% |
| Q1 FY2024 | Mar 31, 2024 | $5.76M | -57.0% |
| Q4 FY2023 | Dec 31, 2023 | $6.98M | +11.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.55M | +59.5% |
| Q2 FY2023 | Jun 30, 2023 | $4.25M | +70.0% |
| Q1 FY2023 | Mar 31, 2023 | $13.39M | +307.4% |
| Q4 FY2022 | Dec 31, 2022 | $6.24M | +1542.8% |
| Q3 FY2022 | Sep 30, 2022 | $4.11M | -52.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.50M | -77.8% |
| Q1 FY2022 | Mar 31, 2022 | $3.29M | -69.3% |
| Q4 FY2021 | Dec 31, 2021 | $380.00K | -97.6% |
| Q3 FY2021 | Sep 30, 2021 | $8.70M | -68.4% |
| Q2 FY2021 | Jun 30, 2021 | $11.27M | -63.3% |
| Q1 FY2021 | Mar 31, 2021 | $10.72M | -55.2% |
| Q4 FY2020 | Dec 31, 2020 | $16.11M | -31.4% |
| Q3 FY2020 | Sep 30, 2020 | $27.52M | +24.2% |
| Q2 FY2020 | Jun 30, 2020 | $30.69M | +38.3% |
| Q1 FY2020 | Mar 31, 2020 | $23.95M | +9.9% |
| Q4 FY2019 | Dec 31, 2019 | $23.49M | +48.8% |
| Q3 FY2019 | Sep 30, 2019 | $22.15M | +73.0% |
| Q2 FY2019 | Jun 30, 2019 | $22.18M | +116.2% |
| Q1 FY2019 | Mar 31, 2019 | $21.78M | +123.1% |
| Q4 FY2018 | Dec 31, 2018 | $15.78M | +90.4% |
| Q3 FY2018 | Sep 30, 2018 | $12.81M | +127.8% |
| Q2 FY2018 | Jun 30, 2018 | $10.26M | +78.0% |
| Q1 FY2018 | Mar 31, 2018 | $9.77M | +53.4% |
| Q4 FY2017 | Dec 31, 2017 | $8.29M | +54.0% |
| Q3 FY2017 | Sep 30, 2017 | $5.62M | +30.3% |
| Q2 FY2017 | Jun 30, 2017 | $5.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.38M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.32M | – |
See a number that looks wrong?